# US 2025/0049940 A1 · Combined Use of Anti-TROP-2 Antibody-drug Conjugate and other Therapeutic Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049940 A1
- Document ID: US20250049940A1
- Status: Published application
- Kind: A1
- Application number: 18/719,435
- Filed: 2023-01-11
- Published: 2025-02-13
- Earliest claimed: 2022-01-13
- Assignees: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Applicants: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Inventors: Xiaoping JIN; Yina DIAO; Qi GUO; Gesha LIU; Lian LU; Yujun WEI; Wenguo YIN; Suxia WANG; Yang PAN; Junyou GE
- Web page: https://patentgrep.com/patent/US20250049940A1

## CPC

- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- C07K 16/30: from tumour cells
- A61K 31/282: Platinum compounds
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 33/243: Platinum; Compounds thereof
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/68037: {the drug being a camptothecin [CPT] or derivatives}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A combination of an anti-TROP-2 antibody-drug conjugate and anti-PD-L1 antibody or other chemotherapeutic drugs such as Carboplatin or Cisplatin, and an application of the combination in the preparation of drugs for preventing and/or treating tumor diseases, wherein the anti-TROP-2 antibody may be Sacituzumab.

## Claims

### Claim at position 1

-27. (canceled)

### Claim 28

A method for treating a cancer in a subject, comprising a step of administering to the subject a therapeutically effective amount of a combination of an anti-TROP-2 antibody-drug conjugate and an additional therapeutic agent, wherein the additional therapeutic agent is one or more selected from the group consisting of an PD-L1 antibody or an antigen-binding fragment thereof and chemotherapeutic agent;
the anti-TROP-2 antibody-drug conjugate comprises a camptothecin drug and an anti-TROP-2 antibody or an antigen-binding fragment thereof, the anti-TROP-2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1 with the sequence as set forth in SEQ ID No.: 1 or a variant thereof, a HCDR2 with the sequence as set forth in SEQ ID No.: 2 or a variant thereof, and a HCDR3 with the sequence as set forth in SEQ ID No.: 3 or a variant thereof, and the light chain variable region comprises a LCDR1 with the sequence as set forth in SEQ ID No.: 4 or a variant thereof, a LCDR2 with the sequence as set forth in SEQ ID No.: 5 or a variant thereof, and a LCDR3 with the sequence as set forth in SEQ ID No.: 6 or a variant thereof;
wherein, the variant has a substitution, deletion or addition of one or more amino acids as compared to the sequence from which it is derived.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a HCDR1 with the sequence as set forth in SEQ ID NO.: 7 or a variant thereof, a HCDR2 with the sequence as set forth in SEQ ID No.: 8 or a variant thereof, and a HCDR3 with the sequence as set forth in SEQ ID No.: 9 or a variant thereof, and the light chain variable region comprises a LCDR1 with the sequence as set forth in SEQ ID No.: 10 or a variant thereof, a LCDR2 with the sequence as set forth in SEQ ID No.: 11 or a variant thereof, and a LCDR3 with the sequence as set forth in SEQ ID No.: 12 or a variant thereof.

### Claim 30 (depends on 28)

The method according to claim 28, wherein the substitution is a conservative substitution.

### Claim 31 (depends on 28)

The method according to claim 28, wherein the antibody or antigen-binding fragment further comprises a framework region derived from a human or murine immunoglobulin.

### Claim 32 (depends on 28)

The method according to claim 28, wherein the chemotherapeutic agent is selected from platinum drugs.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the platinum drug is selected from the group consisting of Cisplatin, Carboplatin, Sulfatodiaminocyctohexane Platin, Nedaplatin, Oxaliplatin, Lobaplatin, Satraplatin, Miboplatin, Enloplatin, Iproplatin, and Dicycloplatin.

### Claim 34 (depends on 28)

The method according to claim 28, wherein the antibody-drug conjugate has the following chemical structure:
wherein γ represents the average number of drug-linker units conjugated to each antibody molecule in the antibody-drug conjugate, and the average number is in the range of 6 to 10.

### Claim 35 (depends on 28)

The method according to claim 28, wherein the average number of γ is between 6 and 9.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the average number of γ is between 6 and 8.

### Claim 37 (depends on 35)

The method according to claim 35, wherein the average number of γ is about 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8 or 7.9.

### Claim 38 (depends on 28)

The method according to claim 28, wherein the cancer is a solid tumor or a non-solid tumor.

### Claim 39 (depends on 28)

The method according to claim 28, wherein the cancer is selected from the group consisting of esophageal cancer, brain tumor, lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, non-Hodgkin's lymphoma, central nervous system tumor, prostate cancer and thyroid cancer.

### Claim 40 (depends on 28)

The method according to claim 28, wherein the cancer is selected from the group consisting of lung cancer, breast cancer and ovarian cancer.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), and epithelial ovarian cancer.

### Claim 42 (depends on 40)

The method according to claim 40, wherein the breast cancer is selected from the group consisting of triple negative breast cancer, HR+/HER2− breast cancer, HR−/HER2+ breast cancer, HR+/HER2+ breast cancer, and BRCA+ breast cancer.

### Claim 43 (depends on 41)

The method according to claim 41, wherein the non-small cell lung cancer is selected from the group consisting of EGFR wild-type or EGFR-mutated non-small cell lung cancers.

### Claim 44 (depends on 41)

The method according to claim 41, wherein the non-small cell lung cancer is selected from the group consisting of advanced/metastatic non-small cell lung cancer.

### Claim 45 (depends on 41)

The method according to claim 41, wherein the non-small cell lung cancer is an ALK rearrangements-negative non-small cell lung cancer.

### Claim 46 (depends on 43)

The method according to claim 43, wherein the EGFR-mutated non-small cell lung cancer is advanced/metastatic, and the mutation of EGFR is single mutation or compound mutation.

### Claim 47 (depends on 28)

The method according to claim 28, wherein the antibody-drug conjugate, anti-PD-L1 antibody or antigen-binding fragment thereof, and Carboplatin or Cisplatin as the chemotherapeutic agent have a cycle of administration of 14 to 42 days.

### Claim 48 (depends on 47)

The method according to claim 47, wherein the cycle of administration is 21 days, 28 days or 42 days.

### Claim 49 (depends on 28)

The method according to claim 28, wherein the antibody-drug conjugate is administered at a dose of 1 mg/kg to 10 mg/kg per time.

### Claim 50 (depends on 28)

The method according to claim 28, wherein the antibody-drug conjugate is administered at a dose selected from the group consisting of 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, and 10 mg/kg per time.

### Claim 51 (depends on 28)

The method according to claim 28, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof is administered at a dose of 900 mg to 1500 mg per time.

### Claim 52 (depends on 51)

The method according to claim 51, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof is administered at a dose selected from the group consisting of 900 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, and 1500 mg per time.

### Claim 53 (depends on 28)

The method according to claim 28, wherein Carboplatin as the chemotherapeutic agent is administered at a dose, calculated as area under curve (AUC), of 1 mg/ml/min to 10 mg/ml/min per time; or, Cisplatin as the chemotherapeutic agent is administered at a dose of 50 mg/m2 to 150 mg/m2 per time.

### Claim 54 (depends on 53)

The method according to claim 53, wherein Carboplatin is administered at a dose, calculated as area under curve (AUC), selected from the group consisting of 1 mg/ml/min, 2 mg/ml/min, and 2.5 mg/ml/min, 3 mg/ml/min, 3.75 mg/ml/min, 4 mg/ml/min, 5 mg/ml/min, 6 mg/ml/min, 7 mg/ml/min, and 8 mg/ml/min per time; or, Cisplatin is administered at a dose selected from the group consisting of 50 mg/m2, 75 mg/m2, 100 mg/m2, 120 mg/m2, and 150 mg/m2 per time.

### Claim 55 (depends on 28)

The method according to claim 28, wherein the subject is a patient with non-small cell lung cancer who previously neither has received an immune checkpoint inhibitor therapy nor has received or at most received a first-line systemic chemotherapy regimen; or the subject is a patient with non-small cell lung cancer who previously has received an adjuvant, neoadjuvant or radical chemoradiotherapy, but the cancer progresses during the therapy or within 6 months after the end of the therapy; or the subject is a patient with non-small cell lung cancer who has received but been failed by an EGFR kinase inhibitor therapy; or the subject is a patient with non-small cell lung cancer who previously neither has received a systemic anti-tumor therapy for locally advanced or metastatic non-small cell lung cancer nor has received an immune checkpoint inhibitor therapy; or the subject is a patient with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who previously has not received a systemic therapy.

### Claim 56 (depends on 28)

The method according to claim 28, which reduces tumor size by at least about 10%.

### Claim 57 (depends on 28)

A kit, which comprises an anti-TROP-2 antibody-drug conjugate and an additional therapeutic agent, wherein the additional therapeutic agent is one or more selected from the group consisting of an anti-PD-L1 antibody or an antigen-binding fragment thereof and a chemotherapeutic agent, wherein the anti-TROP-2 antibody-drug conjugate, anti-PD-L1 antibody or antigen-binding fragment thereof, and chemotherapeutic agent are as defined in claim 28.

### Claim 58 (depends on 28)

A pharmaceutical composition, which comprises an anti-TROP-2 antibody-drug conjugate and an additional therapeutic agent, wherein the additional therapeutic agent is one or more selected from the group consisting of an anti-PD-L1 antibody or an antigen-binding fragment thereof and a chemotherapeutic agent, and the anti-TROP-2 antibody-drug conjugate, anti-PD-L1 antibody or antigen-binding fragment thereof, and chemotherapeutic agent are as defined in claim 28.

### Claim 59 (depends on 58)

The composition according to claim 58, further comprising one or more pharmaceutically acceptable excipients, diluents or carriers.

### Claim 60 (depends on 28)

The method according to claim 28, wherein the variant has a substitution, deletion or addition of 1, 2 or 3 amino acids as compared to the sequence from which it is derived.

### Claim 61 (depends on 47)

The method according to claim 47, wherein the cycle of administration is 21 to 42 days.
